DeepLook Medical, a New Haven, Connecticut-based technology firm focused on visual enhancement technology to advance medical imaging, raised $1.7m in funding.
Connecticut Innovations, Tidal River, Angel Investor Forum (AIF), OKG Capital, Werth Ventures, and various private investors participated in this round.
The company intends to use the funds for talent acquisition and the advancement of next-generation products, expansion of sales and partnerships, support for additional clinical research and publications, and extension of global IP and regulatory protections and clearances.
Led by Marissa Fayer, CEO, DeepLook Medical has developed an AI technology platform designed specifically for the visualization of suspicious masses in dense breasts. The software overlays directly onto existing imaging screens, providing a seamless and efficient workflow enhancement with one-click measurement, segmentation, and visualization.
DL Precise™, the latest flagship product from DeepLook Medical, utilizes the company’s shape-recognition software to delineate tumor morphology, a critical aspect for improved diagnosis.This FDA-cleared software has recently entered the commercial market through partnerships with four major channel partners including Barco, Blackford, Tempus, and Radical Imaging.
Compatible with various imaging modalities, including mammography, ultrasound, CT, and MRI, DL Precise™, employs a single-click deterministic algorithm for precise lesion segmentation, streamlining workflow efficiency. DeepLook Medical is leveraging other complementary AI advances to further enhance the impact and reach of its patented technology.
FinSMEs
08/02/2024